Pasithea Therapeutics Corp.
Clinical trials sponsored by Pasithea Therapeutics Corp., explained in plain language.
-
New pill targets Hard-to-Treat cancers in groundbreaking first trial
Disease control Recruiting nowThis is the first study in people testing an experimental pill called PAS-004. It aims to find a safe dose and understand side effects for adults with advanced solid tumors that have specific genetic mutations (RAS, NF1, or RAF) and have run out of standard treatment options. Par…
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New pill tested to shrink painful NF1 tumors
Disease control Recruiting nowThis early-stage study is testing a new oral medication called PAS-004 in adults with Neurofibromatosis Type 1 (NF1) who have painful, inoperable, or recurring plexiform neurofibroma tumors. The main goals are to find a safe dose, understand the side effects, and see if the drug …
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC